Eureka Therapeutics

Eureka Therapeutics is the [[LiuCheng|刘诚]]-led biotech company discussed in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学. The source says the company began working on [[CARTCellTherapy|CAR-T]] in 2014 and focuses especially on using CAR-T for late-stage solid tumors.

The company’s role in the source is not a full company history. It grounds Liu’s claims about Solid Tumor CAR-T Constraints, including the difficulty of getting engineered immune cells into tumor tissue, keeping them active inside the Tumor Microenvironment, and making the therapy safe enough to scale. The episode says Eureka’s liver-cancer project is in U.S. phase II clinical development and is planned to move toward phase III.

Key Claims

• Eureka is presented as a CAR-T company oriented toward solid-tumor use rather than only blood cancers.
• Its liver-cancer program is used as the concrete company context for Liu’s optimism about CAR-T in difficult cancers.
• The source treats the company as an example of why the next CAR-T frontier is efficacy in solid tumors, not only cheaper manufacturing.

Connections

• [[LiuCheng|刘诚]] - founder and CEO interviewed in the episode.
• CAR-T Cell Therapy, Ex Vivo CAR-T Manufacturing, and In Vivo CAR-T - therapy and manufacturing routes discussed through the company context.
• Solid Tumor CAR-T Constraints and Tumor Microenvironment - main scientific problem space.
• China Cell Therapy Regulatory Dual Track - broader Chinese cell-therapy development environment discussed by Liu.